Gilead Sciences | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Agios Pharmaceuticals USD 76.25M 177.48M 2024-12
ALKERMES USD 291.15M 636.63M 2024-12
Alnylam Pharmaceuticals USD 966.43M 133.49M 2024-12
Amgen USD 11.97B 2.96B 2024-12
Biogen USD 2.38B 675.8M 2024-12
BioMarin Pharmaceutical USD 613.22M 324.54M 2024-12
Bristol-Myers Squibb USD 10.35B 2.46B 2024-12
Eli Lilly USD 3.27B 100.6M 2024-12
Gilead Sciences USD 9.99B 4.95B 2024-12
GlaxoSmithKline GBP 3.87B 678M 2024-12
Glaxosmithkline GBP 3.87B 678M 2024-12
Incyte USD 1.69B 383.72M 2024-12
J&J USD 6.12B 1.28B 2024-12
Merck USD 13.24B 1.35B 2024-12
Moderna USD 1.93B 283M 2024-12
Neurocrine Biosciences USD 233M 116.1M 2024-12
Novartis USD 8.87B 4.74B 2024-12
Pfizer USD 1.04B 49M 2024-12
PTC Therapeutics USD 779.71M 253.71M 2024-12
Regeneron Pharmaceuticals USD 17.91B 15.9B 2024-12
Sanofi 6.8B 1.92B 2024-06
Sarepta Therapeutics USD 1.1B 905.16M 2024-12
United Therapeutics USD 1.7B 143.3M 2024-12
Vertex Pharmaceuticals USD 4.57B 669.6M 2024-12



Gilead Sciences Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Apr 2025.